Zeposia Archives -

The new treatment with ozanimod (also known as zeposia) will benefit over 12,000 adults who suffer from moderate

NICE recommends Celgene’s Ozanimod to treat ulcerative colitis

https://pharmaphorum.com/news/nice-recommends-celgenes-ozanimod-to-treat-ulcerative-colitis/

BMS adds to IBD pipeline with $1.9bn GentiBio deal

Phil Taylor Bristol-Myers Squibb, deucravacitinib, GentiBio, Immunology and inflammation, inflammatory bowel disease, partnering, Treg, Zeposia 0 Comment

Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for

BMS adds to IBD pipeline with $1.9bn GentiBio deal

https://pharmaphorum.com/news/bms-adds-to-ibd-pipeline-with-1-9bn-gentibio-deal/

Open communication helps ulcerative colitis patients through COVID-19

News/ News/ R&D

Pfizer’s Arena buyout looks canny, as etrasimod aces phase 3 trials

Phil Taylor Arena Pharmaceuticals, Bristol-Myers Squibb, etrasimod, Immunology and inflammation, inflammatory bowel disease, Pfizer, ulcerative colitis, Zeposia 0 Comment

Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals’ etrasimod

Pfizer’s Arena buyout looks canny, as etrasimod aces phase 3 trials

https://pharmaphorum.com/news/pfizers-arena-buyout-looks-canny-as-etrasimod-aces-phase-3-trials/

News/ News/ R&D

Etrasimod data suggests Pfizer’s $6.7bn gamble on Arena will pay off

Phil Taylor Bristol-Myers Squibb, etrasimod, Immunology and inflammation, Pfizer, ulcerative colitis, Zeposia 0 Comment

It’s only been two weeks since Pfizer closed its $6.7 billion takeover of Arena Pharmaceuticals, and it already

Etrasimod data suggests Pfizer’s $6.7bn gamble on Arena will pay off

https://pharmaphorum.com/news/etrasimod-data-suggests-pfizers-6-7bn-gamble-on-arena-will-pay-off/

News/ News/ R&D

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

Phil Taylor Arena Pharmaceuticals, Bristol-Myers Squibb, etrasimod, Immunology and inflammation, M&A, Pfizer, ulcerative colitis, Zeposia 0 Comment

Pfizer has found another use for the windfall profits it is making from it BioNTech-partnered COVID-19 vaccine, agreeing

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

https://pharmaphorum.com/news/flush-with-covid-cash-pfizer-tables-6-7bn-bid-for-arena/

Market Access/ News/ News

NICE says final ‘no’ to BMS’ Zeposia for multiple sclerosis

Richard Staines multiple sclerosis, neurology, NICE, Zeposia 0 Comment

NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that

NICE says final ‘no’ to BMS’ Zeposia for multiple sclerosis

https://pharmaphorum.com/news/nice-says-final-no-to-bms-zeposia-for-multiple-sclerosis/

Market Access/ News/ News

BMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitis

Phil Taylor Bristol-Myers Squibb, fda, inflammatory diseases, ulcerative colitis, Zeposia 0 Comment

Bristol-Myers Squibb’s commercial hopes for new multiple sclerosis drug Zeposia have yet to bear fruit thanks to the

BMS eyes May FDA verdict for MS drug Zeposia in ulcerative colitis

https://pharmaphorum.com/news/bms-eyes-may-fda-verdict-for-ms-drug-zeposia-in-ulcerative-colitis/

Market Access/ News/ News

NICE rejects BMS’ Zeposia MS pill in provisional guidance

Richard Staines Bristol-Myers Squibb, cost-effectiveness, market access, multiple sclerosis, Roche, Zeposia 0 Comment

NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing

NICE rejects BMS’ Zeposia MS pill in provisional guidance

https://pharmaphorum.com/market-access-2/nice-rejects-bms-zeposia-ms-pill-in-provisional-guidance/

News/ News/ R&D

Data sets up ulcerative colitis expansion for BMS’ MS drug Zeposia

Phil Taylor Bristol-Myers Squibb, gastroenterology, immunology, Ozanimod, ulcerative colitis, Zeposia 0 Comment

Bristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis –

Data sets up ulcerative colitis expansion for BMS’ MS drug Zeposia

https://pharmaphorum.com/news/data-sets-up-ulcerative-colitis-expansion-for-bms-ms-drug-zeposia/

Trending

Zeposia

Login